A genetic medicine company creating safe, effective and accessible cures for chronic diseases.

Screen Shot 2017-08-28 at 7.18.20 PM.png

Our Company

Mediphage Bioceuticals is a genetic medicine company spun out of the University of Waterloo in Canada, focused on developing SAFE, EFFECTIVE, and ACCESSIBLE gene delivery platforms to unlock the therapeutic power of personalized, redoseable, genetic medicine.


December, 2015

Mediphage Bioceuticals Inc. was formed as a spin off company from the University of Waterloo in Ontario, Canada.

Seed Round.

March, 2016

Mediphage Bioceuticals closes its seed round to develop proof of concept and perform early stage efficacy studies.

Concept Testing.

February, 2017

Mediphage Bioceuticals successfully develops its DNA Ministring production and targeting technology. Mediphage also completes early stage concept and efficacy studies.

MARS Toronto.

March, 2017

Mediphage Bioceuticals moves to the MaRS Innovation Center located in Toronto, Ontario. Mediphage Bio is now entering late stage safety and efficacy studies and is beginning to manufacture DNA Ministrings in compliance with cGMP manufacturing practices.



Screen Shot 2017-08-28 at 8.52.21 PM.png

Our Technology


DNA Ministrings


Mediphage Bioceuticals has developed DNA ministrings (msDNA), the safest transgene delivery vector on the market that does not compromise effectiveness and can be produced at a fraction of the cost of competing solutions.

msDNA is a SAFE, EFFECTIVE and highly ACCESSIBLE nonviral gene delivery vector. Unlike conventional viral and nonviral vectors msDNA’s topology as a linear covalently closed “string” makes it both stable and the safest tool for gene delivery.

msDNA Highlights:

  • msDNA is generated through Mediphage Bioceuticals’ patented E. coliin vivo” production system. Our system is highly scalable because it requires a simple temperature shift to generate large-scale quantities.

  • msDNA is the only vector capable of protecting individuals from harmful mutations in the chromosome by selectively inducing cell death upon harmful integration.

  • msDNA contains no immunostimulatory components which allows for enhanced repeated administration.

With the highest safety profile across viral and nonviral vectors, ministring DNA enhances the transition of current genetic engineering technology into true personalized genetic medicine.


Current Applications of msDNA

msDNA are an efficient, customizable and redosable vector for ex vivo and in vivo gene therapies, cell therapies and gene editing.

Our msDNA is currently being evaluated by big pharmaceutical companies and biotechnology companies looking to develop in vivo DNA vaccines, cell therapies using T/-B engineering, and therapeutics using the CRISPR system.


Our Team


Dr. Roderick Slavcev,

Founder & CEO, HBSc, PhD, MBA, MRSB, C.Biol

  • Associate Professor, Pharmaceutical Sciences

  • Professor, Business & Entrepreneurship School of Pharmacy, University of Waterloo

  • Chartered Biologist, Royal Society of Biology


Nafiseh Nafissi

Director of R&D, PhD, MSc

  • B.W. Pearson Research Medal (2014)

  • University of Waterloo School of Pharmacy Award of Excellence (2013)

Nafiseh Nafissi Headshot.png

Lee Bowman,

Chief Operating Officer

  • MA - International Relations

  • BMath - Computer Science (Bioinformatics)

Lee Bowman Headshot.png

Advisory Board


Dr. Grant Isaac,
CFO, Cameco


Dr. Sanjay Singh, President & CEO, Temple Therapeutics B.V. Director, BioteCanada


Dr. Michael Naso,
Director R&D, Johnson & Johnson


Dr. Jake Thiessen, Associate Dean and Founder, University of Waterloo, School of Pharmacy (retired)

Our Support

Illumina Accelerator_color.png
University of Waterloo.png